AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis
The Journal of Pathology: Clinical Research · 2025
DOI: 10.1002/2056-4538.70028 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2025. Verfasst von Muriel D Brada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins, Carcinoma, Renal Cell, Receptor Protein-Tyrosine Kinases, Kidney Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
Novel treatment options for metastatic renal cell carcinomas (RCC) include specific MET inhibitors, GAS6/AXL inhibitors, and SRC inhibitors. The interplay between c‐MET, SRC, AXL expression, and their gene mutation patterns in different renal carcinoma subtypes is unclear. To improve the understanding of these signaling pathways, we analyzed c‐MET, AXL, and SRC expression in 590 clear cell RCC (ccRCC) and 127 papillary RCC (pRCC) by immunohistochemistry and integrated sequencing data to investigate the frequency of MET, AXL , and SRC gene mutations, their expression levels, and the presence of splice variants. In TCGA and in Foundation Medicine, Inc. (FMI) datasets, AXL and SRC gene alterations were extremely rare (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
- Department of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
- Foundation Medicine, Inc., Cambridge, MA, USA.
- Department of Pathology, Upstate Medical University, Syracuse, NY, USA.
- Department of Urology, Upstate Medical University, Syracuse, NY, USA.
- Department of Medicine (Oncology), Upstate Medical University, Syracuse, NY, USA.
ORCID-Profile: Muriel D Brada, Tülay Karakulak, Martina Haberecker, Dorothea Rutishauser, Daniel Eberli, Holger Moch
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Brada, M. D., Karakulak, T., Schraml, P., Haberecker, M., Rutishauser, D., Ross, J. S., Eberli, D., & Moch, H. (2025). AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.70028
Vancouver
Brada MD, Karakulak T, Schraml P, Haberecker M, Rutishauser D, Ross JS, et al. AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis. The Journal of Pathology: Clinical Research. 2025. doi:10.1002/2056-4538.70028
BibTeX
@article{Brada2025,
author = {Brada, Muriel D and Karakulak, Tülay and Schraml, Peter and Haberecker, Martina and Rutishauser, Dorothea and Ross, Jeffrey S and Eberli, Daniel and Moch, Holger},
title = {AXL and SRC in clear cell renal cell carcinoma: absence of mutations, rare alternative splicing events, but association of protein expression with poor prognosis},
journal = {The Journal of Pathology: Clinical Research},
year = {2025},
doi = {10.1002/2056-4538.70028}
}
EUVIMED